Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Nandy

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Gynecologic Oncology|September 1, 1994
Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer: a randomized studyL Kumar, R Kaushal, M Nandy, et al.
Postgraduate Medicine|October 13, 2009
Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trialMarc R Toglia, Scott R Serels, Christine Laramée, et al.
BJU International|February 20, 2009
Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer StudyFritz H Schröder, Chris H Bangma, Johannes M Wolff, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Gynecologic Oncology|September 1, 1994
Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer: a randomized studyL Kumar, R Kaushal, M Nandy, et al.
Postgraduate Medicine|October 13, 2009
Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trialMarc R Toglia, Scott R Serels, Christine Laramée, et al.
BJU International|February 20, 2009
Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer StudyFritz H Schröder, Chris H Bangma, Johannes M Wolff, et al.
Pageof 2